-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Shijiazhuang Sihua Pharmaceutical Once Again Ranked Among China’s Top 100 Pharmaceutical Companies
Category:
发布时间：2024-09-09
【概要描述】
With lotus flowers in full bloom, vying in beauty and fragrance, the entire city is suffused with their sweet scent. On September 7, the highly anticipated 2023 Top 100 Chinese Pharmaceutical Companies list was officially unveiled in Chengdu, Sichuan Province, drawing widespread attention from the pharmaceutical industry. Shijiazhuang No.4 Pharmaceutical Group once again made the prestigious list, ranking 51st—up five places from the previous year—and was also honored with two awards: “Best Industrial Enterprise for Pharmaceutical R&D Product Lines in China” and “Outstanding Corporate Social Responsibility Case among Chinese Pharmaceutical Enterprises.”
With lotus flowers in full bloom, vying for beauty and fragrance, the entire city is filled with their sweet scent. On September 7, the highly anticipated 2023 Top 100 Chinese Pharmaceutical Companies list was officially unveiled in Chengdu, Sichuan Province, drawing widespread attention from the pharmaceutical industry. Shijiazhuang Sihua Pharmaceutical Group once again made the prestigious list, ranking 51st—up five places from the previous year—and was also honored with two awards: “Best Industrial Enterprise for Pharmaceutical R&D Product Lines in China” and “Outstanding Corporate Social Responsibility Case among Chinese Pharmaceutical Enterprises.”
According to available information, the Top 100 Chinese Pharmaceutical Companies ranking is compiled by the China Pharmaceutical Industry Information Center of the Ministry of Industry and Information Technology based on national statistical data, supplemented by indices that assess enterprises’ new-drug innovation, rational industrial layout, development potential, and market focus. The ranking is conducted at the level of legal entities in the industrial sector, giving it high authority and guiding significance within the industry. It is the most authoritative and socially influential professional evaluation in China’s pharmaceutical sector and is widely regarded as a leading indicator of industry development trends.
As a leading, pillar pharmaceutical enterprise in the industry, the Group has in recent years thoroughly implemented the new development philosophy, taking it as its mission to research, develop, and manufacture more “Chinese medicines” that are tailored to the genetic heritage and physical characteristics of the Chinese population. Centering on the paramount task of high-quality development, the Group has firmly seized the favorable opportunities and supportive policy environment created by the state’s encouragement of the pharmaceutical industry’s growth, kept a keen eye on the cutting edge of industry development, and rigorously pursued an innovation-driven strategy. With a relentless, forward-moving momentum, the Group has leveraged project construction to continuously advance the integrated development of the innovation chain, talent chain, industrial chain, and supply chain, thereby fostering and cultivating new drivers of productivity. By harnessing technological innovation and digital transformation, the Group has empowered the seamless translation of integrated “API–formulation” innovations into market-ready products and facilitated industrial upgrading. As a result, the foundation for the company’s high-quality development has grown ever stronger, while its innovative influence and market competitiveness have achieved a new leap forward.
In 2023, the Group submitted applications for a total of 109 product varieties and obtained approval for 88 new-product manufacturing licenses, achieving industry-leading results in both the number of applications filed and the number of approvals granted. Guided by innovation, the Group has initially established a multi-pronged business development model: innovative drugs serve as the core driver, supported by specialty generic chemical drugs and active pharmaceutical ingredients, pharmaceutical packaging materials, and injectables as key pillars, with biologics and medical devices providing complementary growth.
The group’s leadership stated that it will remain true to its original mission of “producing high-quality medicines for the people,” focus on its core responsibilities and main business, further strengthen the enterprise’s central role in technological innovation, harness innovative approaches and forward-thinking to pool and mobilize innovation resources, pursue high-level scientific and technological breakthroughs, proactively plan and deploy its product pipeline, actively build an integrated, high-performance innovation ecosystem spanning both active pharmaceutical ingredients and finished dosage forms, cultivate new drivers of productivity, accelerate the transition from old to new growth engines, and drive the high-end, intelligent, and green transformation and upgrading of traditional industries through technological innovation. The goal is to translate more innovative achievements into the company’s market, competitive, and developmental advantages, expedite its ascent into the top 50 pharmaceutical companies, and contribute vigorously to the building of a Healthy China.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091